Mahana Therapeutics, Bayer Strike Commercialization Deal


Collaboration to focus on digital therapeutics.

Image Credit: PSG's "Trends in Drug Benefit Design Report"

Image Credit: PSG's "Trends in Drug Benefit Design Report"

Mahana Therapeutics has inked an agreement with the consumer health division of Bayer, aiming to commercialize digital therapeutics (DTx). The agreement, which comes amid Bayer’s recent launch of a new business unit focused on new digitally enabled precision health products, will focus on providing individuals with the opportunity control their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.

Pertaining to DTx, according to PSG's "Trends in Drug Benefit Design Report," 69% of the report's respondents are aware of them, but only 23% of respondents are currently covered under their insurance plans. Further, 39% are considering requesting coverage in the next one to two years. The graphics below also demonstrate these statistics (Figure 15), and for those respondents who are aware, they commented on if their plan covers them (Figure 16).

“This historic partnership is among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics. Mahana is proud to collaborate with the Bayer team who share our view that digital therapeutics are a critical part of the future of healthcare,” said Simon Levy, CEO, Mahana, in a company press release. “Through this agreement, we can further expand the availability of our innovative prescription digital therapeutics for patients and their caregivers around the world who seek effective treatment for chronic conditions.”

Reference: Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics. BusinessWire. August 22, 2023. Accessed August 24, 2023.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.